Can measuring DNA transcription infidelity enable a more personalised approach to treating cancer?
Graham Combe
Founder of the #CreativeDisruption & #AgileLeaders Forums & #BiotechBuddies and #CoffeeBuddies Events
Bernard Bihain, CEO to Genclis SAS is interviewed on PharmaTV
Bernard Bihain, CEO to Genclis SAS, reveals how their diagnostic approach could help clinicians predict the severity of cancers, and devise more optimised treatment plans.
https://www.pharmatelevision.com/Video/1390-PTVNRBernardBihain.aspx